Madden Securities’s ARS Pharmaceuticals SPRY Stock Holding History

Madden Securities’s Portfolio SPRY Stock Details SPRY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$86	Buy	+20	New	+$117	﹤0.01%	342

Other funds holding SPRY

Pavaki Capital Management Pueblo, Colorado $294M AUM 34.46% 1-Year Est. Return

Investment Management Associates Greenwood Village, Colorado $490M AUM 6.7% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Norman Fields Gottscho Capital Management New York $329M AUM 22.06% 1-Year Est. Return

Matisse Capital Portland, Oregon $256M AUM 15.28% 1-Year Est. Return

Profund Advisors Bethesda, Maryland $3.48B AUM 66.96% 1-Year Est. Return

China Universal Asset Management Company Shanghai, China $1.92B AUM 74.14% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

USAdvisors Wealth Management Eden Prairie, Minnesota $351M AUM 13.01% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

Madden Securities's SPRY Position: Q3 2026 in Review

Madden Securities opened a new position in ARS Pharmaceuticals (SPRY) in Q3 2026: 20 shares worth $86. The stake represents ﹤0.01% of the portfolio and ranks #342 among its holdings.

31 funds tracked by Wall St. Rank hold SPRY as of Q3 2026.

Madden Securities held 20 shares of ARS Pharmaceuticals worth $86 as of Q3 2026.
ARS Pharmaceuticals was a new Madden Securities position in Q3 2026.
ARS Pharmaceuticals made up ﹤0.01% of Madden Securities's portfolio in Q3 2026, its #342 holding.
31 funds tracked by Wall St. Rank held ARS Pharmaceuticals as of Q3 2026.

Based on Madden Securities's 13F filing for Q3 2026, filed 27 Oct 2026.